Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Supernus Pharmaceuticals
Deal Size : $450.0 million
Deal Type : Acquisition
Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals
Details : Acquistion will strengthens Parkinson’s disease portfolio with GOCOVRI (amantadine) extended release capsules, the first and only FDA-approved medicine indicated for the treatment of both OFF and dyskinesia in patients with Parkinson’s disease receiv...
Product Name : Gocovri
Product Type : Other Small Molecule
Upfront Cash : $450.0 million
November 24, 2021
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Supernus Pharmaceuticals
Deal Size : $450.0 million
Deal Type : Acquisition
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Supernus Pharmaceuticals
Deal Size : $450.0 million
Deal Type : Acquisition
Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product Portfolio
Details : The transaction will provide Supernus with two marketed products: GOCOVRI (amantadine) extended release capsules, indicated for both OFF and dyskinesia in patients with Parkinson’s disease and Osmolex ER (amantadine) tablets, approved for Parkinson’s...
Product Name : Gocovri
Product Type : Other Small Molecule
Upfront Cash : $450.0 million
November 10, 2021
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Supernus Pharmaceuticals
Deal Size : $450.0 million
Deal Type : Acquisition
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
New Data Analysis Supports GOCOVRI for Motor Complications for People With PD
Details : At week 12, participants treated with GOCOVRI reported statistically significant improvements in motor control for daily activities compared to placebo (least-squares mean changes from baseline of –3.4 points for GOCOVRI and –1.4 for placebo).
Product Name : Gocovri
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 06, 2021
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Approved FDF
Recipient : Osmotica Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Adamas Completes Acquisition of OSMOLEX ER®
Details : Through this acquisition, OSMOLEX ER joins the Adamas portfolio which includes GOCOVRI® extended-release capsules for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy with or without concomitant dopamin...
Product Name : Osmolex ER
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 01, 2021
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Recipient : Osmotica Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Patients enrolled in the pivotal trials increased daily ON time without dyskinesia by 2.9 hours with GOCOVRI compared to placebo, through the reduction of both OFF time and dyskinesia.
Product Name : Gocovri
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 29, 2021
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase IV
Recipient : Oregon Health and Science University
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of GOCOVRI (Amantadine, Extended Release Capsules) on Gait in Parkinson's Disease
Details : Undisclosed
Product Name : Gocovri
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 14, 2020
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Recipient : Oregon Health and Science University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Adamas Announces FDA Filing Acceptance of sNDA to Modify Indication Statement for Gocovri
Details : Adamas has proposed to include GOCOVRI as an appropriate therapy for the treatment of OFF episodes in PD patients receiving levodopa. The clinical evidence supporting GOCOVRI’s effect on OFF time was demonstrated in two large pivotal Phase 3 trials.
Product Name : Gocovri
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 06, 2020
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Approved FDF
Recipient : Osmotica Pharmaceuticals
Deal Size : $7.5 million
Deal Type : Agreement
Osmotica Pharmaceuticals plc Announces Agreement to Settle Patent Litigation with Adamas
Details : Under the terms of the agreement, both parties will drop their respective claims relating to the patent litigation, and Adamas will acquire the global rights to OSMOLEX ER for $7.5 million.
Product Name : Osmolex ER
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 12, 2020
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Recipient : Osmotica Pharmaceuticals
Deal Size : $7.5 million
Deal Type : Agreement
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 25, 2018
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 19, 2018
Lead Product(s) : Amantadine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable